Current challenges in providing good leukapheresis products for manufacturing of CAR-T cells for patients with relapsed/refractory NHL or ALL
Background: T lymphocyte collection through leukapheresis is an essential step for chimeric antigen receptor T (CAR-T) cell therapy. Timing of apheresis is challenging in heavily pretreated patients who suffer from rapid progressive disease and receive T cell impairing medication. Methods: A total o...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
15 May 2020
|
| In: |
Cells
Year: 2020, Jahrgang: 9, Heft: 5 |
| ISSN: | 2073-4409 |
| DOI: | 10.3390/cells9051225 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/cells9051225 Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/2073-4409/9/5/1225 
|
| Verfasserangaben: | Felix Korell, Sascha Laier, Sandra Sauer, Kaya Veelken, Hannah Hennemann, Maria-Luisa Schubert, Tim Sauer, Petra Pavel, Carsten Mueller-Tidow, Peter Dreger, Michael Schmitt, and Anita Schmitt |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 172567937X | ||
| 003 | DE-627 | ||
| 005 | 20230426183832.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200728s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cells9051225 |2 doi | |
| 035 | |a (DE-627)172567937X | ||
| 035 | |a (DE-599)KXP172567937X | ||
| 035 | |a (OCoLC)1341348058 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Korell, Felix |e VerfasserIn |0 (DE-588)1214671659 |0 (DE-627)1725690284 |4 aut | |
| 245 | 1 | 0 | |a Current challenges in providing good leukapheresis products for manufacturing of CAR-T cells for patients with relapsed/refractory NHL or ALL |c Felix Korell, Sascha Laier, Sandra Sauer, Kaya Veelken, Hannah Hennemann, Maria-Luisa Schubert, Tim Sauer, Petra Pavel, Carsten Mueller-Tidow, Peter Dreger, Michael Schmitt, and Anita Schmitt |
| 264 | 1 | |c 15 May 2020 | |
| 300 | |a 17 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 28.07.2020 | ||
| 520 | |a Background: T lymphocyte collection through leukapheresis is an essential step for chimeric antigen receptor T (CAR-T) cell therapy. Timing of apheresis is challenging in heavily pretreated patients who suffer from rapid progressive disease and receive T cell impairing medication. Methods: A total of 75 unstimulated leukaphereses were analyzed including 45 aphereses in patients and 30 in healthy donors. Thereof, 41 adult patients with Non-Hodgkin’s lymphoma (85%) or acute lymphoblastic leukemia (15%) underwent leukapheresis for CAR-T cell production. Results: Sufficient lymphocytes were harvested from all patients even from those with low peripheral lymphocyte counts of 0.18/nL. Only four patients required a second leukapheresis session. Leukapheresis products contained a median of 98 × 108 (9 - 341 × 108) total nucleated cells (TNC) with 38 × 108 (4 - 232 × 108) CD3+ T cells. Leukapheresis products from healthy donors as well as from patients in complete remission were characterized by high TNC and CD3+ T lymphocyte counts. CAR-T cell products could be manufactured for all but one patient. Conclusions: Sufficient yield of lymphocytes for CAR-T cell production is feasible also for patients with low peripheral blood counts. Up to 12–15 L blood volume should be processed in patients with absolute lymphocyte counts ≤ 1.0/nL. | ||
| 650 | 4 | |a apheresis | |
| 650 | 4 | |a CAR T cell | |
| 650 | 4 | |a CD3 positive lymphocytes | |
| 650 | 4 | |a lymphocyte collection | |
| 700 | 1 | |a Sauer, Sandra |d 1975- |e VerfasserIn |0 (DE-588)1060031140 |0 (DE-627)799171778 |0 (DE-576)416132855 |4 aut | |
| 700 | 1 | |a Veelken, Kaya |d 1988- |e VerfasserIn |0 (DE-588)1155327845 |0 (DE-627)1016744269 |0 (DE-576)501617655 |4 aut | |
| 700 | 1 | |a Hennemann, Hannah Mai |e VerfasserIn |0 (DE-588)1214672329 |0 (DE-627)1725692104 |4 aut | |
| 700 | 1 | |a Schubert, Maria-Luisa |d 1982- |e VerfasserIn |0 (DE-588)1147867631 |0 (DE-627)1007273801 |0 (DE-576)49608089X |4 aut | |
| 700 | 1 | |a Sauer, Tim |d 1981- |e VerfasserIn |0 (DE-588)138282013 |0 (DE-627)601099516 |0 (DE-576)307058166 |4 aut | |
| 700 | 1 | |a Müller-Tidow, Carsten |d 1968- |e VerfasserIn |0 (DE-588)1015101798 |0 (DE-627)705330230 |0 (DE-576)351197893 |4 aut | |
| 700 | 1 | |a Dreger, Peter |e VerfasserIn |0 (DE-588)1028891881 |0 (DE-627)732699894 |0 (DE-576)376320966 |4 aut | |
| 700 | 1 | |a Schmitt, Michael |d 1966- |e VerfasserIn |0 (DE-588)133177173 |0 (DE-627)538000600 |0 (DE-576)299672921 |4 aut | |
| 700 | 1 | |a Schmitt, Anita |d 1969- |e VerfasserIn |0 (DE-588)141722495 |0 (DE-627)630587752 |0 (DE-576)325593892 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cells |d Basel : MDPI, 2012 |g 9(2020) Artikel-Nummer 1225, 17 Seiten |h Online-Ressource |w (DE-627)718622081 |w (DE-600)2661518-6 |w (DE-576)365412112 |x 2073-4409 |7 nnas |a Current challenges in providing good leukapheresis products for manufacturing of CAR-T cells for patients with relapsed/refractory NHL or ALL |
| 773 | 1 | 8 | |g volume:9 |g year:2020 |g number:5 |g extent:17 |a Current challenges in providing good leukapheresis products for manufacturing of CAR-T cells for patients with relapsed/refractory NHL or ALL |
| 856 | 4 | 0 | |u https://doi.org/10.3390/cells9051225 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.mdpi.com/2073-4409/9/5/1225 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200728 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 141722495 |a Schmitt, Anita |m 141722495:Schmitt, Anita |d 910000 |d 910100 |e 910000PS141722495 |e 910100PS141722495 |k 0/910000/ |k 1/910000/910100/ |p 12 |y j | ||
| 998 | |g 133177173 |a Schmitt, Michael |m 133177173:Schmitt, Michael |d 910000 |d 910100 |e 910000PS133177173 |e 910100PS133177173 |k 0/910000/ |k 1/910000/910100/ |p 11 | ||
| 998 | |g 1028891881 |a Dreger, Peter |m 1028891881:Dreger, Peter |d 910000 |d 910100 |e 910000PD1028891881 |e 910100PD1028891881 |k 0/910000/ |k 1/910000/910100/ |p 10 | ||
| 998 | |g 1015101798 |a Müller-Tidow, Carsten |m 1015101798:Müller-Tidow, Carsten |d 910000 |d 910100 |e 910000PM1015101798 |e 910100PM1015101798 |k 0/910000/ |k 1/910000/910100/ |p 9 | ||
| 998 | |g 138282013 |a Sauer, Tim |m 138282013:Sauer, Tim |d 910000 |d 910100 |e 910000PS138282013 |e 910100PS138282013 |k 0/910000/ |k 1/910000/910100/ |p 7 | ||
| 998 | |g 1147867631 |a Schubert, Maria-Luisa |m 1147867631:Schubert, Maria-Luisa |d 910000 |d 910100 |e 910000PS1147867631 |e 910100PS1147867631 |k 0/910000/ |k 1/910000/910100/ |p 6 | ||
| 998 | |g 1214672329 |a Hennemann, Hannah Mai |m 1214672329:Hennemann, Hannah Mai |d 910000 |d 910100 |e 910000PH1214672329 |e 910100PH1214672329 |k 0/910000/ |k 1/910000/910100/ |p 5 | ||
| 998 | |g 1155327845 |a Veelken, Kaya |m 1155327845:Veelken, Kaya |d 910000 |d 910100 |e 910000PV1155327845 |e 910100PV1155327845 |k 0/910000/ |k 1/910000/910100/ |p 4 | ||
| 998 | |g 1060031140 |a Sauer, Sandra |m 1060031140:Sauer, Sandra |d 910000 |d 910100 |e 910000PS1060031140 |e 910100PS1060031140 |k 0/910000/ |k 1/910000/910100/ |p 3 | ||
| 998 | |g 1214671659 |a Korell, Felix |m 1214671659:Korell, Felix |d 910000 |d 910100 |e 910000PK1214671659 |e 910100PK1214671659 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN172567937X |e 3730967185 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Felix Korell, Sascha Laier, Sandra Sauer, Kaya Veelken, Hannah Hennemann, Maria-Luisa Schubert, Tim Sauer, Petra Pavel, Carsten Mueller-Tidow, Peter Dreger, Michael Schmitt, and Anita Schmitt"]},"id":{"doi":["10.3390/cells9051225"],"eki":["172567937X"]},"person":[{"given":"Felix","role":"aut","family":"Korell","display":"Korell, Felix"},{"given":"Sandra","role":"aut","family":"Sauer","display":"Sauer, Sandra"},{"display":"Veelken, Kaya","family":"Veelken","given":"Kaya","role":"aut"},{"given":"Hannah Mai","role":"aut","family":"Hennemann","display":"Hennemann, Hannah Mai"},{"display":"Schubert, Maria-Luisa","family":"Schubert","given":"Maria-Luisa","role":"aut"},{"given":"Tim","role":"aut","family":"Sauer","display":"Sauer, Tim"},{"family":"Müller-Tidow","given":"Carsten","role":"aut","display":"Müller-Tidow, Carsten"},{"display":"Dreger, Peter","family":"Dreger","given":"Peter","role":"aut"},{"display":"Schmitt, Michael","role":"aut","given":"Michael","family":"Schmitt"},{"family":"Schmitt","role":"aut","given":"Anita","display":"Schmitt, Anita"}],"relHost":[{"origin":[{"publisher":"MDPI","dateIssuedDisp":"2012-","dateIssuedKey":"2012","publisherPlace":"Basel"}],"pubHistory":["1.2012 -"],"type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"],"note":["Gesehen am 09.05.12"],"id":{"zdb":["2661518-6"],"issn":["2073-4409"],"eki":["718622081"]},"part":{"issue":"5","text":"9(2020) Artikel-Nummer 1225, 17 Seiten","volume":"9","extent":"17","year":"2020"},"title":[{"title_sort":"Cells","title":"Cells","subtitle":"open access journal"}],"physDesc":[{"extent":"Online-Ressource"}],"recId":"718622081","disp":"Current challenges in providing good leukapheresis products for manufacturing of CAR-T cells for patients with relapsed/refractory NHL or ALLCells"}],"origin":[{"dateIssuedKey":"2020","dateIssuedDisp":"15 May 2020"}],"title":[{"title":"Current challenges in providing good leukapheresis products for manufacturing of CAR-T cells for patients with relapsed/refractory NHL or ALL","title_sort":"Current challenges in providing good leukapheresis products for manufacturing of CAR-T cells for patients with relapsed/refractory NHL or ALL"}],"note":["Gesehen am 28.07.2020"],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"recId":"172567937X","physDesc":[{"extent":"17 S."}]} | ||
| SRT | |a KORELLFELICURRENTCHA1520 | ||